Sri International

Other

Stanford Research Institute

Kenneth J Ryan

Masato Tanabe

Wan-Ru Chao

Richard H Peters

Jyanwei Liu

Edward M Acton

John G Johansson

David W Henry

Edward W Grange

Michael Tracy

Gary A Koolpe

Peter Madrid

Charles K Hiebert

Sidharth Chopra

Alan Laibelman

Benzotriazine doxides are disclosed as drugs targeting, including novel compounds of formula I: 

[object Object]

Syntheses of steroids such as 3-hydroxy-7&#x3b1;-methyl-21-[2'-methoxy-4&#x2032;-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate ('SR 16234') and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serves as a starting material or intermediate. The latter compound may be readily prepared from estrone-3-methyl ether. Certain intermediates in these syntheses also have value as therapeutic agents, for example in the treatment of prostate disorders such as prostatic cancer.

Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one

A housing structure assembly includes a hull and a front wall removably coupled to the hull and configured to simulate a front cover of an air conditioner upon inserting the housing structure assembly into a wall or window opening that is shaped and dimensioned to receive the air conditioner.

Animal housing structure and apparatus

Syntheses of steroids such as 3-hydroxy-7&agr;-methyl-21-&lsqb;2&prime;-methoxy-4&prime;-(diethylaminomethyl)-phenoxy&rsqb;-19-norpregna-1,3,5(10)triene citrate (&ldquo;SR 16234&rdquo;) and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serves as a starting material or intermediate. The latter compound may be readily prepared from estrone-3-methyl ether. Certain intermediates in these syntheses also have value as therapeutic agents, for example in the treatment of prostate disorders such as prostatic cancer.

Novel therapeutic agents useful as inhibitors of HLE are provided. The compounds have the structural formula (I) ##STR1## wherein R.sup.1 through R.sup.9, m, n and p are as defined herein. Methods of using the compounds of formula (I) to inhibit serine proteases and to treat physiological conditions and disease states associated with elevated HLE levels are also provided, as are pharmaceutical compositions containing the compounds.

Human leukocyte elastase (HLE) inhibitors, and related pharmaceutical

Disclosed herein is a new procedure for preparing the C.1-2,4-pentadienyl derivatives of 2-deoxyhexopyranoses, as well as a new procedure for allylation of daunosamine. These methods are particularly useful for the preparation of intermediates in the synthesis of adriamycin C-glycosidic analogs which are useful anti-tumor agents. These methods provide the first enabling disclosure of methods to prepare these desired adriamycin and anthrocyclinone C-glycosidic analogs.

C-glycosidic adriamycin analogs

Mesoionic anhydro-5-amino-1,2,3,4-oxatriazolium hydroxides and methods of using the same in the treatment of cancer, said compositions containing, as an active ingredient, one or more compounds having the structure ##STR1## wherein R.sup.1 represents a phenyl or substituted phenyl group and R.sup.2 represents hydrogen or a methyl group.

Mesoionic antitumor compositions and methods for using the same in the

Septacidin analogs, useful as antitumor agents, having the structure ##STR1## where R is a branched or straight chain alkanoyl group of from 12 to 16 carbon atoms. A preferred compound is 6-[4,6-dideoxy-4-(isopalmitoylglycyl)-amino-.beta.-L-glucopyranosylamino]- 9H-purine.

Growing community of inventors

Sunnyvale, CA, United States of America

Kenneth J Ryan